Selecta Biosciences announced that it has entered into a strategic licensing agreement with Takeda Pharmaceutical Company Limited to develop next-generation gene therapies for two indications in the field of lysosomal storage diseases. Selecta Biosciences (biotechnology company) leverages its proprietary ImmTORTM platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses by enabling redosing, The collaboration will allow the two companies to build differentiated gene therapy programs with the opportunity to combine novel platform technologies that aim to solve challenges associated with first-generation gene therapies.
